Neumora Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Selling, General & Admin	56.76	45.48	31.12	24.55	8.39	0.25
Research & Development	193.88	142.72	91.75	55.78	17.31	-
Operating Expenses	250.64	188.19	122.87	80.32	25.71	0.25
Operating Income	-250.64	-188.19	-122.87	-80.32	-25.71	-0.25
Interest & Investment Income	21.49	16.61	4.56	-	-	-
Other Non Operating Income (Expenses)	-0.2	-0.17	0.39	0.01	-0.08	-
EBT Excluding Unusual Items	-229.35	-171.75	-117.92	-80.31	-25.79	-0.25
Merger & Restructuring Charges	-	-	-	-	-0.7	-
Gain (Loss) on Sale of Investments	-	-	0.02	-	-	-
Other Unusual Items	-	-	-	-	-3.28	-
Pretax Income	-293.25	-235.66	-130.9	-237.31	-99.27	-0.25
Income Tax Expense	0.45	0.27	-	-	-	-
Net Income	-293.7	-235.93	-130.9	-237.31	-99.27	-0.25
Net Income to Common	-293.7	-235.93	-130.9	-237.31	-99.27	-0.25
Shares Outstanding (Basic)	158	65	27	22	13	-
Shares Outstanding (Diluted)	158	65	27	22	13	-
Shares Change (YoY)	368.32%	138.99%	24.25%	68.46%	-	-
EPS (Basic)	-1.86	-3.63	-4.81	-10.84	-7.64	-
EPS (Diluted)	-1.86	-3.63	-4.81	-10.84	-7.64	-
Free Cash Flow	-184.86	-163.4	-115.41	-76.24	-28.06	-
Free Cash Flow Per Share	-1.17	-2.51	-4.24	-3.48	-2.16	-
EBITDA	-250	-187.53	-122.28	-79.79	-25.6	-
D&A For EBITDA	0.64	0.67	0.59	0.54	0.11	-
EBIT	-250.64	-188.19	-122.87	-80.32	-25.71	-0.25

Source: S&P Capital IQ. Standard template. Financial Sources.